September 11, 2017 / 11:12 AM / 13 days ago

BRIEF-Shire says drug to reduce HAE met primary endpoints

Sept 11 (Reuters) - Shire Plc:

* INVESTIGATIONAL SUBCUTANEOUS C1 ESTERASE INHIBITOR LIQUID FOR INJECTION SIGNIFICANTLY REDUCES HAE MONTHLY ATTACK RATE VERSUS PLACEBO IN A PHASE 3 PIVOTAL TRIAL

* STUDY MET PRIMARY ENDPOINT AND ALL KEY SECONDARY ENDPOINTS Source text for Eikon: Further company coverage: (Bengaluru Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below